Symbiotics Sicav (Lux.) – Emerging Impact Bond Fund (EIBF)

Symbiotics Sicav (Lux.) – Emerging Impact Bond Fund (EIBF) ticker ( SSEMIAC:LX) makes investment in businesses and projects in emerging markets globally which target Low and Middle Income Households (LMIHs) as well as Micro- Small and Medium-Sized Enterprises (MSMEs) in order to foster access to capital to MSMEs active in low income population segments to create jobs and alleviate poverty.

Through these investments, its aims to foster inclusive development impact and thereby long-term value creation through sustainable principles by promoting the democratization of access to capital to MSMEs active in low income population segments, the Fund seeks to contribute to job creation and poverty alleviation and hence to a sustainable form of globalization (Environment, Social and Governance).

Supporting the development of MSMEs in emerging and frontier markets has proven to be a useful and important tool for promoting sustainable development and boosting economic growth over the long term. At the same time, it generates a stable return for investors which generally has low correlation to traditional financial markets.

The Fund seeks to provide a “money market plus” yield, targeting USD 3-month LIBOR + 1-3% annual net return for a volatility of 1-3% over an investment cycle, resulting from economic value creation at the base of the pyramid in emerging and frontier markets.

Financial description

The Fund is designed for qualified investors with a minimum investment amount of EUR 125,000 equivalent. The Fund targets both specialized and mainstream investors who seek to benefit from the growth potential of emerging and frontier markets and to contribute to the critical development of the MSME sector as the center of innovation and job creation in emerging economies.
----------------
This communication provides general information which is current as at the time of production and is subject to change without notice. This communication is for the use of intended recipients only and the contents may not be reproduced, redistributed or copied in whole or in part for any purpose without Symbiotics’ prior express consent. Not all products offered by Symbiotics are available in all jurisdictions. This communication does not purport to be complete and is qualified in its entirety by reference to the more detailed discussions to be contained in the relevant offering documentation.